CJC-1295 in Inverness — GHRH Analog Research Guide
CJC-1295 research guide for Inverness. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
CJC-1295 in Inverness: Sourcing, Purity & Protocols
For anyone in Inverness trying to locate CJC-1295, the foundational reality is that this compound is distributed via specialist online vendors. The practical takeaway for Inverness researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the framework for evaluating that quality is identical for researchers everywhere. What consistently distinguishes top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for contamination assurance. This guide guides Inverness researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Inverness researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
Quality CJC-1295 sourcing begins with a useful first test: does this vendor share complete COA data without being asked? Vendors who do are operating transparently. The HPLC analytical chromatogram is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. For Inverness researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before placing larger orders is the accepted approach among experienced researchers. Store lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order CJC-1295 — ships to Inverness
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and limited human studies. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — equivalent to 25mcg per unit on an insulin syringe. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results stated as EU/mg and verify they are within the acceptable range for your research context. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is not a licensed human medication and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
